Lead Candidate

all catalysts(0)

nothing on the calendar yet

News(10)

• Foghorn cuts 40% of workforce
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 2d ago
• Novartis wagers almost $8B on a Chinese biotech’s RNA drugs
  In exchange for a $575 million payment up front, Abogen Biosciences will furnish Novartis with access to its RNA technology, including an option to license its lead program ABO-2203.
  biopharma_dive · 2d ago
• 2026 IPO blitz continues with 4 new biotech filings
  With more than 25 companies debuting on the public markets, 2026 has recorded the highest number of biotech IPOs since 2021. Now, four companies—including Iambic Therapeutics and ADARx Pharmaceutic…
  biospace · 12d ago
• Telix buys ITM in bid to create a ‘radiopharmaceutical powerhouse’
  Worth $1.65 billion up front, the deal combines two large pipelines and manufacturing networks, helping Telix potentially “corner the industry” for radiopharmaceuticals, one analyst wrote.
  biopharma_dive · 13d ago
• Citing Replimune approval, experts say localized cancer meds could redefine care
  Delivering therapeutics directly to tumors, as in the case of Replimune’s recently approved Tudriqev and Amgen’s Imlygic, holds advantages, especially when cancer is caught early, but challenges re…
  biospace · 13d ago
• Goa Therapeutics launches with ‘immeasurably huge’ vision of creating Narcan for alcohol
  A new biotech has sprung out of stealth with a bold vision to develop the “greatest therapeutic of all time”—a drug that can quickly sober up people who have had too much to drink.
  fiercebiotech · 17d ago
• Sionna lays off 46% of workforce in strategic shift after cystic fibrosis trial fail
  Sionna Therapeutics is laying off almost half its workforce as the company recovers from the failure of its closely watched cystic fibrosis add-on program.
  fiercebiotech · 19d ago
• Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon
  Cellectis may have kicked off the year promising “huge momentum” in the allogeneic CAR-T space, but even the French biotech has been unable to resist the dominance of in vivo options.
  fiercebiotech · 20d ago
• Alzheon outlines plans for major fundraising round despite Phase 3 miss for Alzheimer's drug
  Alzheon, a biotech that has been attempting to treat Alzheimer's with a checkered drug candidate for more than a decade, is plotting a major fundraise. The Framingham, MA-based biotech outlined an…
  endpoints · 23d ago
• Kura spins diabetes work into a Lilly-backed biotech startup
  Caspian Therapeutics aims to develop menin inhibitors, which have proven effective against leukemia, for diabetes and other cardiometabolic conditions.
  biopharma_dive · 25d ago